glp-1-rezeptoragonisten wohl auch bei Typ-1-Diabetes sinnvoll Mögliche Verbindung zwischen GLP-1-Rezeptoragonisten und

Gene expression analysis showed upregulation of survival pathways (Egr1, Akt1, Kras, Src, Foxo, Srf, VEGFR2, NOS1, NOS3) and downregulation of inflammatory mediators (NOS2, NFB)

In a clinical trial of more than 3,000 adults with obesity, participants who received the highest dose of orforglipron, 36 milligrams, lost 11.2% of their body weight -- about 25 pounds on average -- over more than 16 months

[DOI] [PubMed] [Google Scholar] 89.Cuypers A., Keunen E., Bohler S., Jozefczak M., Opdenakker K., Gielen H., Vercampt H., Bielen A., Schellingen K., Vangronsveld J., et al

This preferential fat-over-muscle regain is what drives the bottom-right box in your diagram sarcopenic obesity.